IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.58
+1.28%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$8.87M
MomentumView details →
1D Return
+1.28%
YTD Return
−59.31%
RSI (14)
40.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$8.87M
RSI (14)
40.8
MomentumView details →
1D Return
+1.28%
YTD Return
−59.31%
SummaryUpdated Jun 1, 2026
Imunon, Inc. (NASDAQ:IMNN) is a clinical-stage biotechnology company founded in 1982 and headquartered in Lawrenceville, New Jersey. Originally known as Celsion Corporation, the company rebranded to Imunon in September 2022 to better reflect its focus on immunotherapy development. The company has been publicly traded since 1999 and specializes in developing DNA-based immunotherapies and vaccines for cancer treatment and infectious diseases. Imunon operates two primary technology platforms and is currently advancing its lead ovarian cancer treatment through Phase III clinical trials while exploring partnerships for its vaccine technologies.
Similar companies
Latest newsMore news →
Imunon, Inc. reported a net loss of $2.8 million for Q2 2026, with a diluted loss per share of $0.54, and provided updates on its clinical studies including OVATION 2 and OVATION 3 trials for IMNN-001.25d agoIMUNON announced that the independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 study without modification.73d agoImunon, Inc. issued $7.72 million aggregate principal amount of secured promissory notes (8% A-1 Note and 5% B Note) due 2027, with proceeds for general corporate purposes.93d ago